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   SIMULTANEOUS ESTIMATION OF 
ETODOLAC AND THIOCOLCHICOSIDE IN 
BULK AND IN TABLET FORMULATION BY 
UV-SPECTROPHOTOMETRY 
Abstract 
Two simple, rapid and reproducible simultaneous equation and Q-analysis UV-
-spectrophotometric methods have been developed for simultaneous esti-
mation of etodolac (ETO) and thiocolchicoside (THC) in combined tablet 
dosage form. The methods involved solving simultaneous equations and
Q-value analysis based on measurement of absorbance at wavelengths, 223 
(λmax of ETO), 259.4 (λmax of THC) and 236 nm (iso-absorptive point). 
Linearity was found in the concentration range of 1–6 µg/mL and 4−24 µg/mL 
for ETO and THC, respectively, with correlation coefficients 0.9998 and 0.9992. 
The amounts of drugs estimated by the proposed methods are in excellent 
agreement with the label claimed. Furthermore, the methods were applied for 
the determination of ETO and THC in spiked human urine. The degradation 
behavior of ETO and THC was investigated under acid hydrolysis, alkali hyd-
rolysis, photo- and oxidative degradation. The subsequently generated samp-
les were used for degradation studies using the developed method. THC was 
found to degrade extensively under alkali hydrolysis and unaffected by other 
stress conditions, while ETO was found to be stable in all stress conditions. 
The methods were validated according to ICH guidelines. The method, suit-
able for routine quality control, has been successfully applied to the deter-
mination of both drugs in commercial brands of tablets. 
Keywords: etodolac, thiocolchicoside, simultaneous equation method, Q- 
absorbance ratio method, spiked human urine, sress degradation study. 
 
 
Etodolac is a nonsteroidal anti-inflammatory 
drug (NSAID) and used as anti-inflammatory and 
analgesic. It is chemically 1,8-diethyl-1,3,4,9-tetrahyd-
ropyrano[3,4-b]indole-1-acetic acid [1-2]. ETO inhibits 
cyclo-oxygenase enzyme and subsequently inhibits 
prostaglandin synthesis, and is hence used as an 
analgesic [3]. Thiocolchicoside is also an anti-inflam-
matory analgesic with muscle relaxant action [4], it is 
chemically  N-[(7S)-3-(beta-D-glucopyranosyloxy)-1,2- 
-dimethoxy-10-(methylsulfanyl)-9-oxo-5,6,7,9-tetra-
hydrobenzo[a]heptalen-7-yl] acetamide [1-2]. THC 
has selective affinity for GABA receptors and activate 
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GABA inhibitory pathway thereby acting as a potent 
muscle relaxant [5]. 
Etodolac is official in Indian Pharmacopoeia [2], 
United State Pharmacopoeia [6] and British Pharma-
copeia [7]. Literature survey reveals one LC-MS [8] 
method was found for estimation of ETO in biological 
fluids. Few RP-HPLC [9-10], UV-spectrophotometric 
[11-14] and HPTLC [15] method have been reported 
for estimation of ETO in combination with other drugs 
in bulk and in pharmaceutical dosage forms. Thiocol-
chicoside is official in Indian Pharmacopoeia [2]. 
Several RP–HPLC [16-21]
, UV-spectrophotometric 
[22-24] and HPTLC [25-26] methods have been stu-
died for determination of THC in bulk and in pharma-
ceutical formulations. Literature survey revealed 
simultaneous estimation of ETO and THC using UV 
spectrophotometric [27] and RP-HPLC [28] methods. 
To the best of our knowledge, UV-spectro-
photometric methods have not been yet reported for R. PANDEY et al.: SIMULTANEOUS ESTIMATION OF ETODOLAC…  Chem. Ind. Chem. Eng. Q. 20 (1) 9−17 (2014) 
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simultaneous estimation of ETO and THC in com-
bined dosage form. In the present work, a successful 
endeavor has been made to estimate both these 
drugs simultaneously in tablet dosage form by two 
simple UV-spectrophotometric methods (simultane-
ous equation method and Q-absorbance ratio 
method) [29]. However, the reported methods have 
poor sensitivity and are applicable only for pharma-
ceuticals and not for biological fluids. The methods 
were successfully applied to the determination ETO 
and THC in spiked human urine. These methods were 
validated according to the ICH guidelines [30-32]. The 
chemical structures of both drugs are as shown in 
Figures 1 and 2. 
 
Figure 1. Chemical structure of etodolac. 
 
Figure 2. Chemical structure of thiocolchicoside. 
MATERIAL AND METHODS 
Chemicals and Reagents 
Thiocolchicoside and etodolac bulk drugs were 
obtained from Vital Lab. Pvt. ltd, Mumbai, and Inchem 
Lab. Pvt. Ltd, Hyderabad, India, respectively, as gift 
samples. Methanol (HPLC grade) was purchased 
from Merck (India) Ltd., Worli, and Mumbai, India. 
Tablet (proxym-MR) was purchased from Indian mar-
ket, containing 200 mg of ETO and 4 mg of THC. 
Drug free human urine was obtained from a healthy 
male aged about 24 years. 
Instrumentation 
A UV-visible spectrophotometer (Shimadzu-
1700, UV Probe 2.21 software) with spectral band-
width 1 nm was employed for all spectroscopic mea-
surements, using a pair of 1.0 cm matched quartz 
cells. 
Selection of common solvent 
Methanol was selected as common solvent for 
studying spectral characteristics of drugs.  
Preparation of stock standard solutions  
Stock standard solutions of ETO and THC were 
separately prepared by dissolving 10 mg in 100 ml 
volumetric flask containing 50 mL methanol and the 
volume was made up to the mark with water to obtain 
final concentrations of 100 µg/mL for each sample. 
Simultaneous equation method (Method-I) 
From the stock solution of 100 µg/mL, working 
standard solutions of drugs were prepared by appro-
priate dilution and scanned in the UV-region, i.e., 
400−200 nm. Linearity was found in the concentration 
range of 1-6 µg/mL and 4−24 µg/mL for ETO and 
THC, respectively (Table 1). From the overlaid spec-
tra (Figures 3 and 4) two wavelengths, 223 (λmax of 
ETO) and 259.4 nm (λmax of THC) were selected for 
the construction of simultaneous equation. Standard 
solutions were prepared at concentrations 1–6 µg/mL 
for ETO and 4–24 µg/mL for THC. The absorbances of 
these standard solutions were measured at 223 and 
259.4 nm and calibration curves were plotted. Two 
simultaneous equations (in two variables C1 and C2) 
were formed using E (1%, 1 cm) values (Table 2). 
= 1E T O T H C 1383.17 +509.67 ACC  (1) 
+ 2E T O T H C =262.66 433.16 AC C  (2) 
where CETO and CTHC are the concentrations in g/100 
mL in sample solution; A1 and A2 are absorbance of 
Table 1. Linearity studies; SEE - standard error of estimate; SD - standard deviation 
Parameter THC  ETO 
Linearity, µg mL
-1 4-24  1–6 
Linearity equation  Y = 0.0335X + 0.0342  Y = 0.1276X + 0.0393 
Slope ± SD  0.0335±0.0001  0.1276±0.0003 
Intercept ± SD  0.0342±0.0005  0.0393±0.0008 
Correlation Coefficient ± SD 
SEE 
Chi-square 
Residual SD 
0.9992±0.0001 
0.00790 
0.00069 
0.0037 
0.9998±0.0003 
0.00343 
0.0001 
0.00307 R. PANDEY et al.: SIMULTANEOUS ESTIMATION OF ETODOLAC…  Chem. Ind. Chem. Eng. Q. 20 (1) 9−17 (2014) 
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mixture at selected wavelength 223 and 259.4 nm, 
respectively. 
By applying Cramer’s rule [26] to Eqs. (1) and 
(2), the concentrations CETO and CTHC can be obtained 
as follows: 
() () =× − × − ETO 2 1 433.16 509.67 / 591451 CA A  (3) 
() ( ) =× −× − THC 1 2 262.66 1383.17 / 591451 CA A  (4) 
Q-Absorbance ratio method (Method-II) 
From the overlain spectrum of ETO and THC, 
two wavelengths were selected one at 259.4 nm, 
λmax of THC and other at 236 nm, which was the 
isoabsorptive point for both drugs. The E (1%, 1 cm) 
values for both the drugs at selected wavelengths are 
shown in Table 2.  
The method employed Q-values, and the con-
centrations of drugs in sample solutions were deter-
mined using the following equations: 
1
THC
1
my
xy
QQ A
C
QQ a x
−
=×
−
 (5) 
2
ETO
1
mx
yx
QQ A
C
QQ a y
−
=×
−
 (6) 
where A1 and A2 are the absorbances of mixture at 
236 and 259.4 nm, Qm = A2/A1, Qy = ay2/ay1 and Qx = 
= ax2/ax1, ax1 (397.66), ax2 (262.66), ay1 (397.83) and 
ay2 (433.16) are absorptivities (1%, 1 cm) of ETO and 
THC at 236 and 259.4 nm. 
Assay of tablet formulation by Method-I and Method-II 
Twenty tablets containing ETO and THC were 
weighed and the mean weight was calculated. These 
tablets were crushed and accurately weighed tablet 
powder equivalent to 10 mg of ETO that contains 0.2 
mg THC was transferred into a 100 mL volumetric 
flask containing 50 mL of methanol, then 9.8 mg of 
THC working standard was added and the volume 
was made up to the mark with water, filtered through 
0.45  μm Whatmann filter paper. An appropriate 
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volume of solution was further diluted with water to 
obtain concentrations 4 μg/mL of ETO and 4 μg/mL of 
THC. Absorbance of sample solution was recorded at 
223, 236 and 259.6 nm and the concentrations of two 
drugs in the sample were determined using Eqs. (3) 
and (4) (Method-I) and (5) and (6) (Method-II). The 
analysis procedure was repeated for six times with 
tablet formulation. The results of analysis are men-
tioned in Table 3. 
 
Percentage recovery studies 
The accuracy of the proposed analytical method 
was determined by recovery experiments. The reco-
very studies were carried out at three different con-
centration levels. A known amount of drug was added 
to pre-analysed tablet formulation at 80, 100 and 
120%, and percentage recoveries were calculated. 
The results of recovery studies were satisfactory and 
are presented in Table 4. 
 
Figure 4. Overlain spectra of ETO and THC and their mixture. 
Table 2. E (1%, 1 cm) value of ETO and THC at 223, 259.4 and 236 nm 
Parameter   (E 1%, 1cm) at 223 nm   (E 1%, 1cm) at 259.4 nm   (E 1%, 1cm) at 236 nm  
ETO  THC  ETO   THC   ETO  THC 
Mean   1383.17  509.67  262.67  433.16  397.66  397.83 
SD   1.83 1.51  1.84 1.94 1.58  1.60 
RSD / %  0.13  0.29  0.69  0.44  0.39  0.40 
Table 3. Results of analysis of tablets by the proposed methods and statistical comparison of the results with the reference method 
Method  Tablet content  Label claim, mg 
Found, label claim±SD, % (n = 6) 
Reference method [33]  Proposed method 
I ETO  200  99.60±0.0032  99.25±0.29,  F Test: 0.0011, t Test: 0.179 
THC 4  104.50±0.0018  98.45±0.55,  F Test: 1.542, t Test: 0.002 
II ETO  200  99.10±0.0021  101.71±0.92,  F Test: 1.496, t Test: 0.038 
THC 4  103.25±0.0031  99.00±0.56,  F Test: 4.865, t Test: 0.0056 R. PANDEY et al.: SIMULTANEOUS ESTIMATION OF ETODOLAC…  Chem. Ind. Chem. Eng. Q. 20 (1) 9−17 (2014) 
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Precision 
Precision of an analytical procedure expresses 
the closeness of agreement between a series of 
measurements obtained from multiple samplings of 
the same homogenous samples under the prescribed 
conditions. The precision of the method was verified 
by intra-day, inter-day and repeatability studies. Intra-
day precision was determined by analyzing three 
different concentrations (4, 5 and 6 µg mL
-1) of ETO 
and THC, for three times in the same day. Day-to-day 
variability was evaluated using the three concen-
trations listed above and analyzed on three different 
days. Repeatability of the sample solution was mea-
sured by taking absorbances of a homogenous 
sample of 4 µg mL
-1 of ETO and 4 µg mL
-1 of THC six 
times. 
Sensitivity 
Sensitivity of the methods for drugs was indi-
vidually determined by calculating the LOD, LOQ and 
Sandell’s sensitivity (µg/cm
2), which can be defined 
as the smallest weight of substance that can be 
detected in the column of solution of unit cross section. 
Analysis of ETO and TCH in human urine 
From stock solutions of ETO and THC, 0.4 mL 
of sample was spiked in 5 ml of human urine and 
centrifuged at 3000 rpm, 4 °C for 10 min, then the 
supernatant was collected and the volume was made 
up with methanol to 10 ml, followed by sonication for 
5 minutes to obtain concentrations of 4 μg/mL of ETO 
and 4 μg/mL of THC. The absorbance was measured 
directly at 223, 236 and 259.6 nm and the concentra-
tions of two drugs in the spiked urine sample [33-35] 
were determined using Eqs. (3) and (4) (Method-I) 
and (5) and (6) (Method-II).  
Stress degradation studies 
The ICH guidelines require stability testing of 
new drug substances and products that to reveal the 
inherent stability characteristics of the active sub-
stance. The aim of the present study was to perform 
the stress degradation studies on ETO and THC 
using the developed method. 
Conduct of stress studies 
Acid and base-induced degradation was 
attempted by adding 10 mg of ETO and THC in 10 mL 
each of 0.1 M HCl and 0.1 M NaOH solutions. The 
solutions were kept for 8 h at room temperature in the 
dark in order to exclude the possible degradative 
effect of light. The solutions were neutralized and 
diluted with methanol. The absorbances were mea-
sured directly at 223, 236 and 259.6 nm. For oxidative 
degradation, 10 mg of ETO and THC was added to 10 
mL of 10% (v/v) hydrogen peroxide solution. The mix-
tures were kept for 8 h. The solutions were diluted 
with methanol and treated as described for acid and 
base-induced degradation. Photodegradation was 
studied by exposing 1 mg/mL solution in methanol to 
sunlight for 72 h. The resulting solutions were diluted 
with methanol and analyzed using the methods des-
cribed above. 
RESULTS AND DISCUSSION 
Etodolac and thiocolchicoside followed linearity 
in the concentration ranges of 1–6 μg/mL and 4–24 
μg/mL, respectively, and results are shown in Table 1 
and Figures 5 and 6. The marketed brand of tablet 
was analyzed and recovery for ETO and THC deter-
mined by proposed methods I and II was found to be 
99.25 and 101.71% for ETO and 98.45 and 99.00% 
for THC, respectively. The  recoveries range from 
99.54 to 101.12% for ETO and THC in Method-I and  
-II, respectively. The results of the proposed method 
were statistically compared with those obtained by the 
reference method [27]. Statistical analysis of the 
results, using Student’s t-test and F-test revealed no 
significant difference between the performance of the 
proposed and reference method at 95% confidence 
level (Table 3). The advantage of the present method 
over the reference method [27] is that the author had 
used 0.1 M NaOH which may be responsible for the 
Table 4. Results of recovery studies 
Level of recovery, %  Amount of drug added, μg/mL Drug 
Recovery, % 
Method-I Method-II 
80 3.2  ETO  100.55  100.42 
3.2 THC  99.86  99.72 
100 4  ETO  99.87  101.12 
4 THC  99.75  99.87 
120 4.8  ETO  99.77  100.68 
4.8 THC  99.54  100.34 
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degradation of thiocolchicoside. Linearity study was 
carried out with good precise range in accordance 
with the dose ration of both drugs in used formulation, 
which were not reported in the reference method. The 
proposed methods are more sensitive because of low 
values of LOD and LOQ and additionally Sandell’s 
sensitivity, as compared to the reference method. 
Percentage label claim of both drugs by the proposed 
methods were found to be equivalent and more pre-
cise over previously published spectrophotometric 
methods. The proposed methods can be applied to 
the determination of ETO and THC in spiked human 
urine. Precision was calculated as inter and intraday 
variations (RSD is less than 2%) for both drugs and 
as repeatability (RSD is less than 2%) and are pre-
sented in Tables 5 and 6. LOD, LOQ and Sandell’s 
Sensitivity of ETO and TCH were found to be suffi-
ciently low (Table 7), showing that much lower amounts 
of both drugs can be effectively detected by these 
methods. Ruggedness for these drugs was carried 
out using two different laboratories and different anal-
ysts; no significant difference was obtained between 
the results in the present study. The specificity and 
selectivity of the method was investigated by observ-
ing any interference encountered from the common 
tablet excipients such as talc, lactose, starch and 
magnesium stearate. These excipients did not inter-
fere with the proposed method. 
Additionally, the developed methods were applied 
to determine ETO and THC in spiked urine sample. 
The recoveries of ETO and THC from spiked human 
urine sample were found to be satisfactory. As shown 
in Table 8, the percentage recovery values in the 
range 90.26 to 94.72 for Method-I as well as Method- 
-II with relative standard deviation values of less than 
2 proved that the accuracy and reproducibility of the 
proposed method for the determination of both the 
drugs simultaneously in spiked human urine. The UV 
spectrum obtained from action of acid, alkali, hyd-
rogen peroxide, and light showed that THC was 
 
 
Figure 5. Calibration curve of THC. 
 
Figure 6. Calibration curve of ETO. R. PANDEY et al.: SIMULTANEOUS ESTIMATION OF ETODOLAC…  Chem. Ind. Chem. Eng. Q. 20 (1) 9−17 (2014) 
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Table 5. Results of precision studies 
Precision (RSD / %)  Method-I  Method-II 
ETO THC  ETO  THC 
Intra–day (n = 3)  0.14  0.15  0.37  0.25 
Inter–day (n = 3)  0.25  0.14  0.14  0.29 
Table 6. Results of repeatability study 
Method  Drug (4 µg/mL)  Amount found in µg/mL (n = 6)  RSD / % 
I ETO  3.98  0.25 
THC 3.96  0.15 
II ETO  3.99  0.14 
THC 3.97  0.21 
Table 7. Sensitivity 
Parameter ETO  TCH 
LOD / µg mL
–1 0.088  0.129 
LOQ / µg mL
–1 0.291  0.949 
Sandell’s sensitivity, µg/cm
2 0.00723  0.0230 
Table 8. Analysis in human urine; amount spiked in urine: 4 µg/mL 
Method  Drug   Amount found, % (n = 5)  RSD / % 
I ETO  92.88  2.86 
THC 94.72  1.98 
II ETO  90.26  2.04 
THC 93.24  2.42 
 
Figure 7. A) ETO in methanol, 0.1 M HCl and 0.1 M NaOH; B) THC in methanol, 0.1 M HCl and 0.1 M NaOH; C) ETO and THC mix in 
methanol, 0.1 M HCl and 0.1 M NaOH. 
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Table 9. Stress degradation studies of ETO and THC 
Sample-exposure condition 
λmax / nm  Recovery, % 
ETO THC  ETO  THC 
0.1 M HCl, 8 h  223  259.6  98.52  99.08 
0.1 M NaOH, 8 h  223  241.2
a 98.69  42.84 
10% H2O2, 8 h  223  259.6  100.21  99.58 
Sunlight, 8 h  223  259.6  100.54  100.20 
aChange in λmax of THC indicates that THC is susceptible to alkali condition and it does some transformation in THC structure 
degraded only by alkali hydrolysis (Figure 7) because 
of change in λmax of THC and there was no effect of 
other stress conditions on THC as well as ETO. The 
amount remaining (%) and recovery (%) were cal-
culated for ETO and THC in stability samples by 
using Eqs. (3) and (4) (Method-I) and (5) and (6) 
(Method-II), Table 9. 
CONCLUSION 
The developed methods were found to be 
simple, accurate and rapid for the routine estimation 
of ETO and THC in tablet formulation as well as in 
human urine. Degradation products resulting from 
stress studies did not interfere with the simultaneous 
estimation of ETO and THC except alkali conditions. 
The methods were validated according to ICH guide-
lines. The method, suitable for routine quality control, 
has been successfully applied to the determination of 
both drugs in commercial brands of tablets. 
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NAUČNI RAD 
   SIMULTANO ODREĐIVANJE ETODOLAKA I 
TIOKOLČIKOZIDA U FARMACEUTSKOJ 
SUPSTANCI I TABLETAMA 
U radu su razvijene dve jednostavne, brze i reproduktivne spektrofotometrijske metode za 
simultano određivanje etodolaka (ETO) i tiokolčikozida (THC) u tabletama koje sadrže obe 
aktivne supstance. Metode uključuju rešavanje sistema jednačina uz korišćenje rezultata 
merenja apsorbanci na 223 nm (λmax za ETO), 259,4 (λmax za THC) i 236 nm (izo-apsorp-
tivna tačka). Nađeno je da pod optimalnim uslovima za reakcije važi Berov zakon u 
opsegu koncentracija 1-6 µg/mL, odnosno 4-24 µg/mL za THC, odnosno ETO, a odgova-
rajući koeficijenti korelacije su 0,9998 i 0,9992. Količine određenih aktivnih supstanci su u 
odličnom slaganju sa količinama koje su označene na etiketi leka. Takođe, metode su 
uspešno primenjene za određivanje ETO i THC u ljudskom urinu. Ispitana je degradacija 
ETO i THC u uslovima kisele i bazne hidrolize i foto i oksidacione degradacije. Nastali 
degrdacioni produkti su analizirani razvijenom metodom. Nađeno je da se tiokolčikozid 
intenzivno razgrađuje u uslovima bazne hidrolize, a da je otporan na druge ispitivane 
uslove, dok je etodolak stabilan na sve ispitivane uslove. Metode su validirane u skladu sa 
ICH smernicama. Metoda je uspešno primenjena za određivanje obe aktivne supstance u 
tabletama i pogodna je za rutinsku kontrolu. 
Ključne reči: etodolak, tiokolčikozid, simultana metoda, Q-apsorpciona metoda, 
ljudski urin, forsirane degradacije leka. 
 
 